Novacyt SA (LSE:NCYT) - Share price


Stock Report

Novacyt SA NCYT

Last Price
GBX412.60

Day Change
-2.60|-0.63%

As of 06/05/2021
17:58:41 BST | GBX
Minimum 15 Minutes Delay.

Last Close415.20p
Day Range410.60 - 436.00
Mkt Cap295.70Mil
52-Wk Range202.75 - 1,276.00
Yield %-
ISINFR0010397232
Volume638,866
P/E8.57
P/S14.43
P/CF-179.39

Share Price

Total Returns 05/05/2021

 Chg (%)  
More ...
Novacyt SA-39.39 
FTSE 100 TR GBP4.75
 
Financials
201720182019
More ...
Income Statement
Turnover12.7513.7213.08
Operating Profit-0.04-0.52-1.24
Net Profit-3.49-2.11-3.90
Reported EPS-0.15-0.06-0.08
Balance Sheet
Current Assets10.917.726.83
Non Current Assets23.1222.5024.16
Total Assets34.0232.5131.07
Current Liabilities7.799.897.69
Total Liabilities---
Total Equity24.9120.1414.59
Cash Flow
Operating Cash Flow-4.65-1.25-1.07
Net Change in Cash1.52-3.200.58
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
12/11/2020PurchaseMr. Jean-Pierre Jacques Crinelli9.701,54114,948.00
11/11/2020PurchaseGraham D. Mullis817.0060,875497,349.00
10/11/2020PurchaseDr. Edwin Snape715.001,0807,722.00
03/06/2020PurchaseDr. Andrew John William Heath305.003,1619,641.00

Company Profile

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. Its diagnostic products are used in LBC, oncology, microbiology, hematology, and serology testing. The company operates its business through two business segments: Corporate and Diagnostics and Molecular Products.The Corporate and Diagnostics segment corresponds to diagnostic activities in laboratories, and the manufacturing and distribution of reagents and kitsfor bacterial and blood tests. The Molecular Products segment represents the activities of Primerdesign, which designs, manufactures and distributes test kits for certaindiseases in humans, animals and food products.

Sector

Diagnostics & Research

Index

FTSE AIM 100 , FTSE AIM All-Share

Next Event 29/06/2021

Final Results
Ratios
Comp
More ...
PER (E)9.40
Div Yld (E)0.00
PEG (E)0.00
ROCE-12.20
Op Mrgn-0.10
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Executive Director, Chief Executive OfficerMr. Graham D. Mullis
Non-Executive DirectorDr. Andrew John William Heath
Non-Executive DirectorDr. Edwin Snape
Executive Director, Chief Corporate Development Officer (CCDO). Both appointments are with immediate effect.Mr. Anthony Stephen Dyer
Non-Executive Director, ChairmanMr. James Christopher Wakefield
Non-Executive DirectorMr. Jean-Pierre Jacques Crinelli
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.